Melody Cobleigh to Paclitaxel
This is a "connection" page, showing publications Melody Cobleigh has written about Paclitaxel.
Connection Strength
0.137
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27; 357(26):2666-76.
Score: 0.074
-
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
Score: 0.026
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8.
Score: 0.020
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
Score: 0.017